Inclusion Criteria:

          1. Provision to sign and date the consent form.

          2. Stated willingness to comply with all study procedures and be available for the
             duration of the study.

          3. Be a male or female aged 18-100.

          4. Have newly diagnosed, resectable cT3-T4 or node positive adenocarcinoma of the
             esophagus or gastroesophageal junction as assessed by CT or MRI of the chest, abdomen
             and pelvis and by endoscopic ultrasound, with pathologic diagnosis obtained within 3
             months of signing consent, without delivery of prior chemotherapy or radiation
             therapy.

          5. Subjects must be previously untreated with systemic chemotherapy or radiation therapy.

          6. Subjects must be deemed a candidate for trimodality therapy (radiation, chemotherapy
             and surgery) based upon multidisciplinary evaluation with plan for preoperative
             chemoradiation followed by surgical resection.

          7. ECOG performance status score of 0-1 (See Appendix).

          8. Adequate bone marrow function (WBC > 3 x 109/L; hemoglobin > 9 g/dl; platelets > 100 x
             109/L)

          9. Adequate liver function (total bilirubin < 1.5 x upper limit of normal, AST < 3 x
             upper limit of normal, and ALT < 3 x upper limit of normal)

         10. Serum creatinine < 1.5 x ULN or calculated creatinine clearance > 50 mL/min (using the
             Cockcroft-Gault formula)

             Males:

             Creatinine CL (mL/min) = Weight (kg) x (140 - Age) 72 x serum creatinine (mg/dL)

             Females:

             Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine
             (mg/dL)

         11. Women of child-bearing potential (WOCBP) must have a negative serum or urine pregnancy
             test within 2 weeks prior to study enrollment and must agree to follow instructions
             for method(s) of contraception for the duration of the study period and at least 3
             months after the last dose of chemotherapy is administered. For the purpose of this
             study, a woman is considered of childbearing potential following menarche and until
             becoming post-menopausal unless permanently sterile. Permanent sterilisation methods
             include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

             For the purpose of this study, methods that can achieve a failure rate of less than 1%
             per year when used consistently and correctly are considered as highly effective birth
             control methods and acceptable contraception. Such methods include:

               -  combined (estrogen and progestogen containing) hormonal contraception associated
                  with inhibition of ovulation:

               -  oral

               -  intravaginal

               -  transdermal

               -  progestogen-only hormonal contraception associated with inhibition of ovulation:

               -  oral

               -  injectable

               -  implantable

               -  intrauterine device (IUD)

               -  intrauterine hormone-releasing system (IUS)

               -  bilateral tubal ligation

               -  vasectomized partner

               -  sexual abstinence

         12. WOCBP who are continuously not heterosexually active are exempt from contraceptive
             requirements but still must undergo pregnancy testing as described in this section.

         13. Males who are sexually active with WOCBP must agree to follow instructions for methods
             of contraception for the duration of the study period and for at least 3 months
             (duration of sperm turnover) after the last dose of chemotherapy is administered. In
             addition, males must be willing to refrain from sperm donation during this time.

        Azoospermic males are exempt from contraceptive requirements.

        Exclusion Criteria:

          1. Subjects with metastatic or inoperable esophageal or gastroesophageal junction
             adenocarcinoma.

          2. Subjects with esophageal or gastroesophageal junction squamous cell carcinoma or
             adenosquamous carcinoma.

          3. Prior treatment with chemotherapy or radiation therapy for esophageal or
             gastroesophageal adenocarcinoma.

          4. Prior malignancy active within the previous 3 years, except for early stage cancers
             treated with curative intent, including basal or squamous cell carcinoma of the skin,
             superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast.

          5. Prior history of thoracic or abdominal radiotherapy that would overlap with the
             planned treatment volume.

          6. Active collagen vascular disease.

          7. Subjects with > Grade 1 peripheral neuropathy.

          8. Any serious or uncontrolled medical disorder or active infection, that in the opinion
             of the investigator may increase the risk associated with study participation, study
             treatment administration or would impair the ability of the subject to receive study
             treatment.

          9. Known history of hepatitis B or hepatitis C.

         10. Clinically unstable cardiac disease including unstable angina, congestive heart
             failure, ventricular arrhythmia or known prior QTc > 450msec.

         11. History of allergy or hypersensitivity to any of the study drugs or study drug
             components.

         12. Any contraindications to any of the study drugs of the chemotherapy regimens (FLOT or
             carboplatin/paclitaxel) selected by the investigator. Investigators should refer to
             the local package insert of the chemotherapy drugs.

         13. Prisoners or subjects who are involuntarily incarcerated.

         14. History of psychiatric illness that precludes completion of informed consent process,
             or which is deemed by the investigators as potentially influencing study compliance.

         15. Known dihydropyrimidine dehydrogenase (DPD) deficiency.

         16. Pregnant or breast-feeding women.